Table 4.
Associations of factors in patients with or without lymph node invasion stratified by the third quartile of body mass index of the patient population
| No lymph node invasion (n=309) | Lymph node invasion (n=52) | |||||
|---|---|---|---|---|---|---|
| BMI ≤28 kg m−2 | BMI >28 kg m−2 | P | BMI ≤28 kg m−2 | BMI >28 kg m−2 | P | |
| Patients (n) | 230 | 79 | 39 | 13 | ||
| Age (year) | 65 (61–70) | 66 (61–70) | 0.804 | 67 (62–70) | 65 (59.5–68) | 0.346 |
| BMI (kg m−2) | 24.3 (23.1–36.1) | 29.7 (28.7–30.8) | <0.0001 | 24.7 (22.4–27.4) | 30.5 (29.0–31.8) | <0.0001 |
| PSA (ng ml−1) | 6.6 (4.9–8.7) | 7.2 (4.3–10.0) | 0.177 | 7.8 (5.0–12.7) | 12.4 (6.1–23.8) | 0.148 |
| TT (ng dl−1) | 460.2 (367.7–548.0) | 344.0 (277.8–438.0) | <0.0001 | 443.0 (358.2–508.4) | 390.0 (318.0–471.5) | 0.232 |
| PV (ml) | 38.7 (30.0–49.0) | 42.9 (32.0–59.0) | 0.015 | 45.0 (36.0–60.0) | 45.0 (29.5–65.0) | 0.916 |
| BPC (%) | 33 (21–50) | 39 (25–57) | 0.470 | 50 (35–71) | 67 (50–100) | 0.071 |
| PGG, n (%) | 0.065 | 0.714 | ||||
| One - three | 168 (73.0) | 49 (62.0) | 9 (23.1) | 4 (30.8) | ||
| Four - five | 62 (27.0) | 30 (38.0) | 30 (76.9) | 9 (69.2) | ||
| pT, n (%) | ||||||
| 2–3a | 204 (88.7) | 66 (83.5) | 0.284 | 20 (51.3) | 6 (46.2) | 1.000 |
| 3b | 26 (11.3) | 13 (16.5) | 19 (48.7) | 7 (53.8) | ||
| SM, n (%) | ||||||
| Negative | 169 (73.5) | 56 (70.9) | 0.655 | 19 (48.7) | 6 (46.2) | 1.000 |
| Positive | 61 (26.5) | 23 (29.1) | 20 (51.3) | 7 (53.8) | ||
| PW (g) | 50.0 (40.0–62.0) | 60.0 (48.0–70.6) | <0.0001 | 57.0 (46.0–70.0) | 55.0 (43.5–74.0) | 0.767 |
| LN (n) | 26 (20–33) | 25 (19–32) | 0.496 | 27 (22–36) | 29 (22.5–41) | 0.363 |
| Positive lymph nodes (n) | 1 (1–2) | 2 (1–3.5) | 0.048 | |||
BMI: body mass index; PSA: prostate-specific antigen; TT: total testosterone; PV: prostate volume; BPC: biopsy positive core; PGG: pathological Grade Group; pT: pathological T stage; SM: surgical margins status; PW: prostate weight; LN: lymph node